Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life

Peptide receptor radionuclide therapy (PRRT), developed over the last two decades, is carried out using radiopharmaceuticals such as 90Y-DOTA-Tyr3-octreotide and 177Lu-DOTA-Tyr3-octreotate (177Lu-Dotatate). These radiocompounds are obtained by labeling a synthetic somatostatin analog with a β-emitti...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Onco Targets Ther
Главные авторы: Severi, Stefano, Grassi, Ilaria, Nicolini, Silvia, Sansovini, Maddalena, Bongiovanni, Alberto, Paganelli, Giovanni
Формат: Artigo
Язык:Inglês
Опубликовано: Dove Medical Press 2017
Предметы:
Review
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5293504/
https://ncbi.nlm.nih.gov/pubmed/28203088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S97584
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы